Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. Read More
Source link
Wall Street strategists are divided over valuations
A version of this post first appeared at TKer.co Wall Street strategists are almost unanimously bullish on the outlook for earnings. for S&P 500 earnings in 2026 range from $300…





